Figure S1. A549 cells were treated with DMSO, 5 µM Fer-1, 2 µM RSL3 or 2 µM RSL3 + 5 µM Fer-1 for 24 h and the cell viability was determined by Cell Counting Kit-8. ****P<0.0001. All experiments were repeated three times. Fer-1, ferrostatin-1; RSL3, RAS-selective lethal 3; ns, not significant.
Figure S2. LUCAT1 expression in liver cancer cells treated with ferroptosis inducers, based on data deposited in the GEO database. (A) LUCAT1 expression in HepG2 cells treated with Erastin and control HepG2 cells. (B) LUCAT1 expression in sorafenib-resistant Hep3B cells and control cells. (C) LUCAT1 expression in sorafenib-resistant Huh7 cells and control cells. *P<0.05, **P<0.01. LUCAT1, lung cancer-associated transcript 1; GEO, Gene Expression Omnibus; IR, sorafenib-resistant cell line obtained by treating cells with increasingly higher concentration of sorafenib; CR, sorafenib-resistant cell line obtained by treating cells with a consistently high concentration of sorafenib; ns, not significant.
Figure S3. LUCAT1 is highly expressed in lung cancer. (A) Box plot showing LUCAT1 expression in cancer from the Pan-Cancer Atlas Hub of UCSC Xena (normal=712, tumour=9784) cohort. (B) Box plot of LUCAT1 expression in LUAD (n=515) and adjacent normal tissues (n=59). (C) Box plot of LUCAT1 expression in LUSC (n=498) and adjacent normal tissues (n=50). (D) LUCAT1 expression was detected using reverse transcription-quantitative PCR in the BEAS-2B normal lung epithelial cell line and the lung cancer cell lines, A549 and H460. ***P<0.001, ****P<0.0001. All experiments were repeated three times. LUCAT1, lung cancer-associated transcript 1; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.